Instylla, Inc. announced that it recently submitted the final module of its premarket approval (PMA) application to the FDA ...

In this final PMA module, Instylla has submitted clinical study resultsto the FDA, advancing our pursuit of the indication ...

The global Embolic Protection Devices Market is valued at $601 million in 2023 and is projected to reach $1,250 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 8.5% from 2024 to ...

The "liquid embolic agent" used as the glue in this embolization technique is called Onyx and is made by Medtronic, which funded the new trial. The embolization is minimally invasive: Doctors ...

Embolic problems result in a greater degree of ischemia than thrombosis, as the embolus characteristically lodges in a "virgin" vascular bed with no prior collateral development. On the contrary ...

Instylla, Inc. is a privately held company based in Bedford, MA, focused on developing novel resorbable embolic agents to advance interventional radiology, with initial clinical applications in ...